

Please cite the Published Version

Bye, AP, Unsworth, AJ and Desborough, MJ (2018) Erratum: Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib (Blood Advances (2017) 1: 26 (2610-2623) DOI: 10.1182/bloodadvances.2017011999). Blood Advances, 2 (23). p. 3515. ISSN 2473-9529

DOI: <https://doi.org/10.1182/bloodadvances.2018028944>

Publisher: American Society of Hematology

Version: Published Version

Downloaded from: <https://e-space.mmu.ac.uk/627782/>

Usage rights: © In Copyright

Additional Information: Copyright The American Society of Hematology

Enquiries:

If you have questions about this document, contact openresearch@mmu.ac.uk. Please include the URL of the record in e-space. If you believe that your, or a third party's rights have been compromised through this document please see our Take Down policy (available from <https://www.mmu.ac.uk/library/using-the-library/policies-and-guidelines>)

Bye AP, Unsworth AJ, Desborough MJ, et al. Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib. *Blood Adv.* 2017;1(26):2610-2623.

In “Acknowledgments” on page 2621 of the 12 December 2017 issue, funding from British Heart Foundation grant RG/15/2/31224 was not mentioned. The error has been corrected in the published article.

DOI 10.1182/bloodadvances.2018028944

© 2018 by The American Society of Hematology